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Sipuleucel-T was approved as a treatment for men with advanced metastatic, castration-resistant prostate cancer on
the basis of improved survival in randomized clinical trials. A major challenge for this therapy, as well as other
newer cancer immunotherapy agents, has been to identify markers that can identify patients who benefit from
these therapies. In a recent manuscript by Sheikh and colleagues, the investigators evaluated changes in T cell
clonality in the peripheral blood and tumors of patients treated with sipuleucel-T using next generation sequencing
of T cell receptor Vß CDR3 sequences. Their findings are discussed in the context of this trial and other cancer
immunotherapies.
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Editorial
An editorial on: Sheikh, N., J. Cham, L. Zhang, T. DeVries,
S. Letarte, J. Pufnock, D. Hamm, J. Trager, and L. Fong.
"Clonotypic Diversification of Intratumoral T Cells Fol-
lowing Sipuleucel-T Treatment in Prostate Cancer Sub-
jects." Cancer Res. 2016;76:3711-18.
Dramatic treatment responses with T-cell checkpoint
inhibitors for multiple tumor types, and CAR-T cell ap-
proaches for B cell malignancies, led the journal Science
to declare that cancer immunotherapy was the scientific
breakthrough of the year in 2013 [1]. Over the last
6 years several immune based treatments have been
FDA approved for multiple types of cancer, creating a
major paradigm shift in the treatment of many malig-
nancies. One of the first therapies to be approved was
sipuleucel-T, an antigen-specific vaccine approved in
2010 for patients with advanced, metastatic, castration-
resistant prostate cancer. This treatment was approved
on the basis of overall improved survival in patients re-
ceiving sipuleucel-T, compared with those receiving pla-
cebo, in a phase III randomized trial, with similar
improved survival observed in other phase III trials [2].
While studies using sipuleucel-T have shown very little
toxicity from treatment [3], a major challenge with the
use of sipuleucel-T in clinical practice is that it has been
difficult to determine if an individual patient has bene-
fited. That is, few changes in serum PSA or objective
radiographic responses are observed after this therapy,
changes deemed important by most patients and treating
physicians as markers of benefit. Notwithstanding, pa-
tients receiving this therapy overall live longer, and ap-
pear to have delays in the development of symptomatic
disease [4]. This has been observed in animal models of
anti-tumor vaccines as well, where tumors may continue
to grow, but at a slower pace [5]. This type of treatment
effect has also been suggested based on models for an-
other prostate cancer vaccine, rilimogene galvacirepvec/
rilimogene glafolivec (Prostvac®, Bavarian Nordic), that is
currently being evaluated in a multinational, randomized
phase III clinical trial [6]. Retrospective studies have also
suggested that patients with lower disease burden may
have greater benefit from sipuleucel-T in terms of over-
all survival than patients with rapidly growing disease
[7]. Together, these have suggested that certain patients
may benefit more than others from this therapy. Conse-
quently, there has been a need for both predictive and
treatment biomarkers to identify patients likely to bene-
fit, and then demonstrate early after therapy whether a
patient might have benefitted [8]. Because this treatment
is a vaccine targeting a tissue-specific protein, prostatic
acid phosphatase (PAP), a logical biomarker evaluation
has been whether patients develop systemic immune re-
sponses to this target. In fact, the development of
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antibody responses to PAP was associated with greater
benefit in terms of overall survival [9]. Moreover, in
other retrospective studies, the development of immune
responses to other, non-targeted tumor-associated pro-
teins, a process known as “antigen spread,” was also as-
sociated with overall longer survival [10].
Similar needs to identify predictive and treatment bio-
markers have occurred following the development of T-
cell checkpoint inhibitors such as agents targeting
CTLA-4 or PD-1/PD-L1. While objective disease re-
sponses do occur in patients treated with these agents,
sometimes these responses can occur months after be-
ginning therapy [11]. In the absence of radiographic re-
sponse, markers to suggest when it is appropriate to
continue or abandon these therapies in favor of other
treatments are not currently available. However, because
these therapies do not act specifically on tumor cells or
tumor-specific T cells, but rather affect the global T-cell
repertoire, it has not been possible to evaluate immune
responses to individual tumor-specific targets such as
for a vaccine like sipuleucel-T. Consequently, most bio-
marker efforts have focused on identifying changes
within the tumor microenvironment following these
therapies [12]. Earlier studies used immunohistochemis-
try or flow cytometry to evaluate the cell populations
that might be altered within a tumor, evaluating specific-
ally for CD4 and CD8 T cells. In murine studies, the de-
velopment of CD8 T-cell infiltration has been associated
with better anti-tumor responses [13]. Next generation
sequencing (NGS) of the complementarity-determining
region 3 (CDR3) from rearranged T-cell receptor (TCR)
variable beta (Vß) from tumor biopsies has more re-
cently permitted not only the quantitative evaluation of
the frequency of T cells within a tissue sample, but also
the diversity of T cells, in a fashion irrespective of need-
ing to know what the TCR recognizes. Recent studies
using this approach have identified that this approach
can be used to evaluate the clonality or diversity of T
cells within human tumor specimens [14, 15].
In a recent report by Sheikh, Fong and colleagues in
Cancer Immunology Research, the authors use NGS of
TCR Vß CDR3 sequences to identify changes in T-cell
populations both in circulation and within prostate tu-
mors from patients with early stage prostate cancer
undergoing treatment with sipuleucel-T [16]. These pa-
tients received sipuleucel-T prior to prostatectomy as part
of a clinical trial (NCT00715104). While the number of
patients evaluated was small, and the authors acknowledge
this, importantly they also included evaluation of tissues
from a small number of patients who received standard
prostatectomy without sipuleucel-T and volunteer blood
donors in their analysis to control for natural variation
over time. They report that treatment was associated with
a decrease in TCR diversity in the peripheral blood over
4 weeks of sipuleucel-T treatment. TCR diversity was
higher, however, in prostatectomy specimens from pa-
tients treated with sipuleucel-T compared with samples
from contemporary patients undergoing prostatectomy
without prior treatment. Finally, they identified a higher
association of peripheral blood TCR signatures with
tumor-associated TCR signatures in patients treated with
sipuleucel-T over the course of treatment. They interpret
these findings to suggest that sipuleucel-T modulated the
tumor-associated immune response, potentially by in-
creasing the antigen-specific immune repertoire, thus nar-
rowing the diversity of T cells in the peripheral
circulation. The increased correlation of TCR signatures
in the periphery and tumor over the period of treatment
suggests that treatment-associated T cells were infiltrating
the tumor, and this was further reflected by the increased
diversity of T cells at the time of prostatectomy in these
individuals compared with patients not receiving
sipuleucel-T.
What does this study teach us about sipuleucel-T and
prostate cancer? First, the findings of increased TCR di-
versity in prostate tumors after treatment with
sipuleucel-T are consistent with findings from other
studies suggesting that active immunotherapies elicit
measurable changes within the tumor microenviron-
ment, and increasing TCR diversity might be a “good”
thing. Clemente and colleagues, studying large granular
lymphocyte leukemia with similar techniques, found a
low diversity of TCR species at baseline, suggesting that
growing tumors may be characterized by a low diversity,
and/or non-functional, infiltrating T cells [17]. Page and
colleagues recently reported that increased tumor T-cell
frequency was elicited in patients with breast cancer
treated with ipilimumab, and that combining this with
cyroablation led to increased T-cell numbers and TCR
diversity [14]. While the specificity of T cells affected
was not determined in the study by Sheikh and col-
leagues, the changes observed suggests that sipuleucel-T
can have an immune-mediated effect within the tumor,
supporting the proposed mechanism of action. What is
not clear is why TCR diversity would be narrowed in the
circulation following sipuleucel-T treatment, proposed
to be due to an antigen-specific cell amplification, but
then broadened in the tumor microenvironment. In fu-
ture studies with sipuleucel-T or other vaccines, it would
be helpful to know whether the magnitude of T-cell in-
filtration was affected by treatment, as would be implied
by a previous report of this trial [18], but using the TCR
sequencing approach. In addition, knowing the specifi-
city of TCR that were amplified would be advantageous,
to mechanistically confirm that T cells amplified are spe-
cific for the PAP target and/or antigens recognized as
those targeted by antigen spread following sipuleucel-T
treatment. Unfortunately, because sipuleucel-T has not
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been extensively studied in this neoadjuvant setting, it is
not possible to determine whether any particular indi-
viduals “benefited” from treatment, and whether the
changes observed were associated with clinical outcome.
Thus larger populations with measurable clinical out-
comes will be necessary to determine whether changes
in TCR diversity might be developed as treatment or
predictive biomarkers for sipuleucel-T.
This study is also important by suggesting that
changes in T-cell repertoire in the peripheral blood
can be measured in response to immunotherapy. This
is particularly relevant for prostate cancer, a disease
for which early recurrent disease can be detected be-
fore the appearance of metastases by radiographic im-
aging, and for which many metastatic sites are not
amenable to biopsy. This may be applicable to other
vaccines for prostate cancer or other malignancies,
and to other immunotherapy approaches as well.
There have been extensive analyses of phenotypic
changes in T-cell populations that might be associated
with benefit from T-cell checkpoint blockade, however
there have been fewer evaluations of the peripheral
blood T-cell response in terms of specificity or diver-
sity of response. One study by Postow et al. suggested
that a low baseline diversity of TCR frequency was
associated with a worse outcome following treatment
with ipilimumab [19]. Previous studies by Fong and
Robert suggested that increasing TCR diversity after
ipilimumab treatment was associated with a better
outcome [20, 21]. Studies evaluating whether changes
in peripheral blood TCR diversity are associated with
better outcome following PD-1/PD-L1 inhibition are
underway. There have, however, been extensive ana-
lyses of antigen-specific T-cell frequencies following
active vaccination. Many of these studies have not
identified an association between antigen-specific im-
munity and clinical outcome. It seems logical that in-
creasing clonality of T cells following vaccination, as
in the study of Sheikh and colleagues, could be due
to amplification of T cells specific for the target anti-
gen. Alternatively, it is conceivable that oligoclonal expan-
sion of several T-cell species, or CD4 and CD8 species
together, might lead to a more favorable outcome than ex-
pansion of a single species. Such a finding would be con-
sistent with the recent identification that antigen spread
to multiple other cancer-associated proteins was associ-
ated with greater benefit following treatment with
sipuleucel-T [10]. These will be important studies for the
future, and may provide common measures of favorable
change in T-cell immunity following different types of im-
mune therapy, whether by vaccines or checkpoint inhib-
ition. Further, the ability to identify changes in the
peripheral blood that are associated with changes in the
tumor microenvironment could lead to the development
of prognostic and treatment biomarkers from peripheral
blood samples, an approach more feasible for the majority
of tumor types, including prostate cancer, than serial
tissue biopsies.
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